PATENT CLAIM ANALYSIS

Application Number: 16300162
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "210200"]

Abstract:
The present invention provides a 2,4,6-trisubstituted s-triazine compound represented by general formula (I) or pharmaceutically acceptable salts, prodrugs or solvates thereof, a preparation method therefor, and use of these compounds in preparing drugs for preventing or treating diseases associated with protein kinase and vimentin dysregulation, and cell vacuolization, and in particular, drugs for treating or preventing cancer growth and metastasis, tissue fibrosis and atherosclerosis.

Claim (Index 5):
The compound, pharmaceutically acceptable salt, prodrug or solvate of  claim 1 , wherein the compound has a structure represented by Formula (I-1), (I-2) or (I-3): wherein, in Formula (I-1) or (I-2),\n R 1  is hydrogen, halogen or nitro; \n R 2  is selected from a group consisting of morpholinyl, pyrrolidinyl, piperazinyl, and azetidinyl, which are optionally substituted with hydroxyl or C 1 -C 6  alkyl; and \n R 3  is halogen or COR a ; wherein R a  is OH or NR 7 R 8 , wherein R 7  and R 8  are independently selected from a group consisting of C 1 -C 6  alkyl optionally substituted with NR 9 R 10 , and C 1 -C 6  alkyl substituted with 3-(C 2 -C 6  alkynyl)-3H-diaziridinyl; or R 7 , R 8  and the nitrogen atom bonded to them form a saturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from N or O, and optionally substituted with C 1 -C 6  alkyl; wherein R 9  and R 10  are independently selected from a group consisting of hydrogen and C 1 -C 6  alkyl; or R 9 , R 10  and the nitrogen atom bonded to them form a saturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from N or 0; \n in Formula (I-3),\n R 1  is H; \n R 2  is morpholinyl; \n R a  is OH or NR 7 R 8 , wherein R 7  and R 8  are independently selected from a group consisting of C 1 -C 6  alkyl optionally substituted with NR 9 R 10 , and C 1 -C 6  alkyl substituted with 3-(C 2 -C 6  alkynyl)-3H-diaziridinyl; or R 7 , R 8  and the nitrogen atom bonded to them form a saturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from N or O, and optionally substituted with C 1 -C 6  alkyl; wherein R 9  and R 10  are independently selected from a group consisting of hydrogen and C 1 -C 6  alkyl; or R 9 , R 10  and the nitrogen atom bonded to them form a saturated 4 to 6-member heterocyclic ring containing optionally an additional heteroatom selected from N or O.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 98.0
- Lexical Diversity: 1.37037
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15752896', '15533048', '14369559', '10763105', '15128471']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8100905903616843
- 35 USC 102 Novelty (BERT): 0.526132812715654
- Combined Prediction Score: 0.7816948125970813
- Mean Citation Score: 329.125342
- Max Citation Score: 335.1889
- Similarity Product: 272.94058545529845

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test